KPV by prescription in the US

KPV is a very short peptide made of three amino acids: lysine, proline and valine. Their one-letter codes, K, P and V, give it its name. It is the tail end of a hormone the body makes called alpha-MSH. All KPV sold today is made in a lab.

You may also see it called Lys-Pro-Val, lysine-proline-valine, or alpha-MSH 11-13.

It is not FDA approved for any use. The FDA found no KPV product authorized in Europe, and no standard drug reference book in Europe or Japan lists it.

Online, KPV is promoted for gut problems such as colitis and Crohn's disease, for skin conditions such as psoriasis and eczema, and for wound healing. The FDA found no studies of KPV in people for any use, as the evidence section below explains.

Compounding is when a licensed pharmacy makes a drug for one patient on a prescription. Under federal law, a 503A pharmacy can usually only use ingredients that pass one of three tests. The ingredient is part of a drug the FDA has approved, has a USP monograph, or is on the FDA's 503A bulks list. KPV passes none of them.

From September 2023 to April 22, 2026, the FDA kept KPV on its Category 2 list. That list flags ingredients that may pose serious safety risks. KPV came off it after the groups that nominated it withdrew. HHS says neither step changed its legal status.

On July 23, 2026, the FDA's compounding advisory committee narrowly voted in favor of adding KPV to the 503A bulks list. According to Healio, a medical news site, the vote was 8 to 6, with one abstention. FDA staff had advised against it. The vote is advice only, and the FDA has not made a final decision.

On October 30, 2026, HHS published a notice in the Federal Register, FR Doc 2026-22192. HHS Secretary Robert F. Kennedy, Jr. signed it. The notice points to an HHS policy that lists six peptides, and KPV is one of them.

HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed doctor that compounds KPV under the policy's conditions. This lasts until a final FDA rule decides whether KPV goes on the 503A bulks list.

This is not FDA approval and it is not a final rule. The notice calls the policy a draft and takes public comments for two weeks. HHS says the policy is not binding and may be revisited if a safety or quality problem appears.

For KPV, the policy covers only forms put on the skin, such as creams and gels, and forms taken by mouth, such as capsules. It names the acetate salt form, called KPV acetate.

KPV injections and nasal sprays are outside the policy. Some sites sell KPV as a shot, so check the form before you agree to a plan.

Each product may contain only one active ingredient. Blends that mix KPV with BPC-157, TB-500 or other peptides, including blends sold under names like KLOW, fall outside the policy.

For forms taken by mouth, the pharmacy must keep proof that its exact formula is absorbed well enough in people. HHS says this is hard to achieve with peptides. The FDA's 2026 review found no human studies of how KPV is absorbed by any route.

The raw peptide must come from a maker registered with the FDA. Each lot needs a certificate of analysis. It must show tests for identity, purity, strength and contaminants such as endotoxins, heavy metals and microbes.

The label must say: "This is a compounded drug product. Not for resale." The pharmacy must report serious side effects and quality problems to the FDA through MedWatch.

Start with a visit, in person or by video, with a licensed prescriber. They should review your health history, your current medicines and why you want KPV. They decide whether a prescription is right for you.

The prescriber must be licensed in the state where you are at the time of the visit, or be allowed to practice there. HHS telehealth guidance says this. Ask which states they are licensed in before you book.

The prescription then goes to a state-licensed 503A compounding pharmacy. The pharmacy makes the product for you alone, with your name on it. The policy does not cover the larger 503B outsourcing facilities.

States set their own rules for pharmacies that ship in from out of state, and some require them to register first. Not every pharmacy can ship to every state, so ask before you pay.

In a proper prescription route, a prescriber approves you before you can check out for the peptide. A site that sells KPV with no prescription, or as "research use only", is not using this route.

Most KPV research is lab work on cells and studies in mice and rats. In mice with colitis, KPV given in drinking water lowered signs of gut inflammation. Other rodent studies looked at skin wound healing. Animal results do not show that it works in people.

There is no published human trial of KPV. The FDA's July 2026 review found no studies of KPV given to people by any route. The nomination cited nine papers, and none of them tested KPV in humans.

When we searched ClinicalTrials.gov on October 30, 2026, we found no registered trials of KPV. A PubMed search the same day found no human clinical trials either.

Even how KPV works is unclear. The FDA says its targets in the body remain unknown.

For creams and gels, a lab study on donated human skin found that KPV passes through skin poorly. The FDA says this could limit how well a cream works.

HHS says it now has records of how widely KPV is used. That is data on use, not proof that it works or is safe. The FDA notes there are approved treatments for wounds and for inflammatory conditions such as psoriasis and eczema.

The FDA found no human safety data for KPV. It also found no standard animal safety studies, including tests for cancer risk and for harm in pregnancy. It says the safety risks in people are unknown.

The FDA's side effect database had no reports for KPV. But 503A pharmacies have generally not reported side effects to the FDA, so no reports does not mean no risk. The new policy requires them to report serious ones.

Peptides can trigger immune reactions and can clump together, which can add risk. The FDA says there is not enough data to rule this out for KPV.

Ask your prescriber: Which states are you licensed in? Is there an approved medicine for my condition that I should try first? What side effects should I watch for, and who do I contact? Is it safe with my other medicines, or if I am pregnant?

Ask the pharmacy: What is your name, and are you a 503A pharmacy licensed to ship to my state? Who made the raw KPV, and is that maker registered with the FDA? Can I see the certificate of analysis for my lot? Is KPV the only active ingredient? For capsules, do you have proof they are absorbed in people?

If you have a side effect, tell your prescriber. You can also report it to the FDA through MedWatch.

We checked 250 US sellers across the six peptides in the HHS policy. 45 ranked providers list KPV. Another 11 list it but are not ranked, each with the reason on this page.

Listed KPV prices cover very different things, from single capsules to monthly plans and blends. So we do not give one price range here. Compare like with like, and check whether the product is a single-ingredient cream or capsule.

We also found 2 sellers offering KPV with no real prescription check, often as "research use only". We do not rank them or name them here.

Legal checks carry the most weight in our scores. We look for a state license, a prescription before checkout, single-ingredient products, routes the policy covers, and any FDA warning letters. Selling KPV injections or blends costs points. Quality checks include a named, FDA-registered ingredient maker and batch certificates of analysis.

Prices and fees change often. Check them, and the states served, on the provider's own page before you book a visit. The research for this page was done on October 29, 2026.